A differential diagnosis method for systemic CAEBV and the prospect of EBV-related immune cell markers via flow cytometry

References

• Cohen JI. Epstein-Barr virus infection. N Engl J Med. 2000;343(7):1–18. doi: 10.1056/NEJM200008173430707.
   Web of Science ®Google Scholar
• Fujiwara S, Nakamura H. Chronic active Epstein-Barr virus infection: is it immunodeficiency, malignancy, or both? Cancers (Basel). 2020;12(11):3202. doi: 10.3390/cancers12113202.
   PubMed Web of Science ®Google Scholar
• Kimura H. EBV in T-/NK-cell tumorigenesis. Adv Exp Med Biol. 2018;1045:459–475.
   PubMed Web of Science ®Google Scholar
• Fernandez-Pol S, Silva O, Natkunam Y. Defining the elusive boundaries of chronic active Epstein-Barr virus infection. Haematologica. 2018;103(6):924–927. doi: 10.3324/haematol.2018.193714.
   PubMed Web of Science ®Google Scholar
• Zhang P, Zeng C, Cheng J, et al. Determination of Epstein-Barr virus-infected lymphocyte cell types in peripheral blood mononuclear cells as a valuable diagnostic tool in hematological diseases. Open Forum Infect Dis. 2019;6(5):ofz171.
   PubMed Web of Science ®Google Scholar
• Kimura H, Ito Y, Kawabe S, et al. EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases. Blood. 2012;119(3):673–686. doi: 10.1182/blood-2011-10-381921.
   PubMed Web of Science ®Google Scholar
• Cohen JI, Jaffe ES, Dale JK, et al. Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood. 2011;117(22):5835–5849. doi: 10.1182/blood-2010-11-316745.
   PubMed Web of Science ®Google Scholar
• Cohen JI, Iwatsuki K, Ko YH, et al. Epstein-Barr virus NK and T cell lymphoproliferative disease: report of a 2018 international meeting. Leuk Lymphoma. 2020;61(4):808–819. doi: 10.1080/10428194.2019.1699080.
   PubMed Web of Science ®Google Scholar
• Bollard CM, Cohen JI. How I treat T-cell chronic active Epstein-Barr virus disease. Blood. 2018;131(26):2899–2905. doi: 10.1182/blood-2018-03-785931.
   PubMed Web of Science ®Google Scholar
• Campo E, Jaffe ES, Cook JR, et al. The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee. Blood. 2022;140(11):1229–1253. doi: 10.1182/blood.2022015851.
   PubMed Web of Science ®Google Scholar
• Quintanilla-Martinez L, Swerdlow SH, Tousseyn T, et al. New concepts in EBV-associated B, T, and NK cell lymphoproliferative disorders. Virchows Arch. 2022;482(1):227–244. doi: 10.1007/s00428-022-03414-4.
   PubMed Web of Science ®Google Scholar
• Zambello R, Teramo A, Barilà G, et al. Activating KIRs in chronic lymphoproliferative disorder of NK cells: protection from viruses and disease induction? Front Immunol. 2014;5:72. doi: 10.3389/fimmu.2014.00072.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH CE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (Eds). WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. IARC: Lyon; 2017.
   Google Scholar
• Dávila Saldaña BJ, John T, Bonifant C, et al. High risk of relapsed disease in patients with NK/T-cell chronic active Epstein-Barr virus disease outside of asia. Blood Adv. 2022;6(2):452–459. doi: 10.1182/bloodadvances.2021005291.
   PubMed Web of Science ®Google Scholar
• Quintanilla-Martinez LKY-H, Kimura H, Jaffe ES. EBV-positive T-cell and NK-cell lymphoproliferative diseases of childhood: IARC, Lyon, France, 2017.
   Google Scholar
• Sawada A, Inoue M, Kawa K. How we treat chronic active Epstein-Barr virus infection. Int J Hematol. 2017;105(4):406–418. doi: 10.1007/s12185-017-2192-6.
   PubMed Web of Science ®Google Scholar
• Kimura H, Cohen JI. Chronic active Epstein-Barr virus disease. Front Immunol. 2017;8:1867. doi: 10.3389/fimmu.2017.01867.
   PubMed Web of Science ®Google Scholar
• Collins PJ, Fox CP, George L, et al. Characterizing EBV-associated lymphoproliferative diseases and the role of myeloid-derived suppressor cells. Blood. 2021;137(2):203–215. doi: 10.1182/blood.2020005611.
   PubMed Web of Science ®Google Scholar
• Yonese I, Sakashita C, Imadome KI, et al. Nationwide survey of systemic chronic active EBV infection in Japan in accordance with the new WHO classification. Blood Adv. 2020;4(13):2918–2926. doi: 10.1182/bloodadvances.2020001451.
   PubMed Web of Science ®Google Scholar
• Arai A. Chronic active Epstein-Barr virus infection: a bi-faceted disease with inflammatory and neoplastic elements. Immunol Med. 2018;41(4):162–169. doi: 10.1080/25785826.2018.1556030.
   PubMedGoogle Scholar
• Arai A. Chronic active Epstein-Barr virus infection: the elucidation of the pathophysiology and the development of therapeutic methods. Microorganisms. 2021;9(1):180. doi: 10.3390/microorganisms9010180.
   PubMed Web of Science ®Google Scholar
• Zheng M, Bao Y, Wang J, et al. The superiority of Epstein-Barr virus DNA in plasma over in peripheral blood mononuclear cells for monitoring EBV-positive NK-cell lymphoproliferative diseases. Hematol Oncol. 2022;40(3):381–389. doi: 10.1002/hon.2998.
   PubMed Web of Science ®Google Scholar
• Yosuke A, Kei M, Naotaka S, et al. Chronic active EBV infection in refractory enteritis with longitudinal ulcers with a cobblestone appearance: an autopsied case report. J BMC Gastroenterol. 2021;21(1):6.
   Google Scholar
• Richter J, Quintanilla-Martinez L, Bienemann K, et al. An unusual presentation of a common infection. Infection. 2013;41(2):565–569. doi: 10.1007/s15010-012-0321-y.
   PubMed Web of Science ®Google Scholar
• Henter JI, Horne A, Aricó M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124–131. doi: 10.1002/pbc.21039.
   PubMed Web of Science ®Google Scholar
• Wang Z, Kimura S, Iwasaki H, et al. Clinicopathological findings of systemic Epstein-Barr virus-positive T-lymphoproliferative diseases in younger and older adults. Diagn Pathol. 2021;16(1):48. doi: 10.1186/s13000-021-01107-1.
   PubMed Web of Science ®Google Scholar
• Suzuki R, Suzumiya J, Nakamura S, et al. Aggressive natural killer-cell leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK cells. Leukemia. 2004;18(4):763–770. doi: 10.1038/sj.leu.2403262.
   PubMed Web of Science ®Google Scholar
• Chan JJE, Ralfkiaer E, et al. Aggressive NK-cell. Leukemia: IARC, Lyon, France; 2008.
   Google Scholar
• Oshimi K. Leukemia and lymphoma of natural killer lineage cells. Int J Hematol. 2003;78(1):18–23. doi: 10.1007/BF02983235.
   PubMed Web of Science ®Google Scholar
• Tse E, Kwong YL. How I treat NK/T-cell lymphomas. Blood. 2013;121(25):4997–5005. doi: 10.1182/blood-2013-01-453233.
   PubMed Web of Science ®Google Scholar
• Chan JQ, Ferry J, et al. Extranodal NK/T-cell lymphoma, nasal type: IARC, Lyon, France, 2008.
   Google Scholar
• Pileri SAW, Sng I, Nakamura S, et al. Peripheral T-cell lymphoma, NOS: IARC, Lyon, France, 2017.
   Google Scholar
• Montes-Mojarro IA, Kim WY, Fend F, et al. Epstein - Barr virus positive T and NK-cell lymphoproliferations: morphological features and differential diagnosis. Semin Diagn Pathol. 2020;37(1):32–46. doi: 10.1053/j.semdp.2019.12.004.
   PubMed Web of Science ®Google Scholar
• El-Mallawany NK, Curry CV, Allen CE. Haemophagocytic lymphohistiocytosis and Epstein-Barr virus: a complex relationship with diverse origins, expression and outcomes. Br J Haematol. 2022;196(1):31–44. doi: 10.1111/bjh.17638.
   PubMed Web of Science ®Google Scholar
• Cho EY, Kim KH, Kim WS, et al. The spectrum of Epstein-Barr virus-associated lymphoproliferative disease in korea: incidence of disease entities by age groups. J Korean Med Sci. 2008;23(2):185–192. doi: 10.3346/jkms.2008.23.2.185.
   PubMed Web of Science ®Google Scholar
• Lin J, Wu H, Gu L, et al. Clinicopathologic findings of chronic active Epstein-Barr virus infection in adults: a single-center retrospective study in China. Clin Exp Med. 2021;21(3):369–377. doi: 10.1007/s10238-021-00689-w.
   PubMed Web of Science ®Google Scholar
• Kawamoto K, Miyoshi H, Suzuki T, et al. A distinct subtype of Epstein-Barr virus-positive T/NK-cell lymphoproliferative disorder: adult patients with chronic active Epstein-Barr virus infection-like features. Haematologica. 2018;103(6):1018–1028. doi: 10.3324/haematol.2017.174177.
   PubMed Web of Science ®Google Scholar
• Wu X, Wang K, Gao Y, et al. Acute fibrinous and organizing pneumonia complicated with hemophagocytic lymphohistiocytosis caused by chronic active Epstein-Barr virus infection: a case report. BMC Infect Dis. 2021;21(1):1207. doi: 10.1186/s12879-021-06868-0.
   PubMed Web of Science ®Google Scholar
• Kimura H, Hoshino Y, Hara S, et al. Differences between T cell-type and natural killer cell-type chronic active Epstein-Barr virus infection. J Infect Dis. 2005;191(4):531–539. doi: 10.1086/427239.
   PubMed Web of Science ®Google Scholar
• Kimura H, Morishima T, Kanegane H, et al. Prognostic factors for chronic active Epstein-Barr virus infection. J Infect Dis. 2003;187(4):527–533. doi: 10.1086/367988.
   PubMed Web of Science ®Google Scholar
• de Lima M, Oran B, Champlin RE, et al. CC-486 maintenance after stem cell transplantation in patients with acute myeloid leukemia or myelodysplastic syndromes. Biol Blood Marrow Transplant. 2018;24(10):2017–2024. doi: 10.1016/j.bbmt.2018.06.016.
   PubMed Web of Science ®Google Scholar
• Shafiee A, Shamsi S, Kohandel Gargari O, et al. EBV associated T- and NK-cell lymphoproliferative diseases: a comprehensive overview of clinical manifestations and novel therapeutic insights. Rev Med Virol. 2022;32(4):e2328.
   PubMed Web of Science ®Google Scholar
• Ondrejka SL, Hsi ED. Chronic active Epstein-Barr virus infection: a heterogeneous entity requiring a high index of suspicion for diagnosis. Int J Lab Hematol. 2020;42 Suppl 1:99–106. doi: 10.1111/ijlh.13199.
   PubMed Web of Science ®Google Scholar
• Kim WY, Montes-Mojarro IA, Fend F, et al. Epstein-Barr virus-associated T and NK-cell lymphoproliferative diseases. Front Pediatr. 2019;7:71. doi: 10.3389/fped.2019.00071.
   PubMed Web of Science ®Google Scholar
• Yu S, Yang Q, Wu J, et al. Clinical application of Epstein-Barr virus DNA loads in Epstein-Barr virus-associated diseases: a cohort study. J Infect. 2021;82(1):105–111. doi: 10.1016/j.jinf.2020.11.027.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Jaffe ES, Brousset P, et al. Cytotoxic T-cell and NK-cell lymphomas: current questions and controversies. Am J Surg Pathol. 2014;38(10):e60-71–e71. doi: 10.1097/PAS.0000000000000295.
   PubMed Web of Science ®Google Scholar
• Arai A. Advances in the study of chronic active Epstein-Barr virus infection: clinical features under the 2016 WHO classification and mechanisms of development. Front Pediatr. 2019;7:14. doi: 10.3389/fped.2019.00014.
   PubMed Web of Science ®Google Scholar
• Chen S, Wei A, Ma H, et al. Clinical features and prognostic factors of children with chronic active Epstein-Barr virus infection: a retrospective analysis of a single center. J Pediatr. 2021;238:268–274.e262. doi: 10.1016/j.jpeds.2021.07.009.
   PubMed Web of Science ®Google Scholar
• Lin J, Chen X, Wu H, et al. Peripheral blood lymphocyte counts in patients with infectious mononucleosis or chronic active Epstein-Barr virus infection and prognostic risk factors of chronic active Epstein-Barr virus infection. Am J Transl Res. 2021;13(11):12797–12806.
   PubMed Web of Science ®Google Scholar
• Arai A, Sakashita C, Hirose C, et al. Hematopoietic stem cell transplantation for adults with EBV-positive T- or NK-cell lymphoproliferative disorders: efficacy and predictive markers. Bone Marrow Transplant. 2016;51(6):879–882. doi: 10.1038/bmt.2016.3.
   PubMed Web of Science ®Google Scholar
• Kimura H, Hoshino Y, Kanegane H, et al. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood. 2001;98(2):280–286. doi: 10.1182/blood.v98.2.280.
   PubMed Web of Science ®Google Scholar
• Arai A, Nogami A, Imadome K, et al. Sequential monitoring of serum IL-6, TNF-α, and IFN-γ levels in a CAEBV patient treated by plasma exchange and immunochemotherapy. Int J Hematol. 2012;96(5):669–673. doi: 10.1007/s12185-012-1170-2.
   PubMed Web of Science ®Google Scholar
• Onozawa E, Shibayama H, Imadome KI, et al. [Inflammatory cytokine production in chronic active Epstein-Barr virus infection]. [Rinsho Ketsueki] Jpn J Clin Hematol. 2017;58(3):189–196.
   PubMedGoogle Scholar
• Tsuchiya S. Diagnosis of Epstein-Barr virus-associated diseases. Crit Rev Oncol Hematol. 2002;44(3):227–238. doi: 10.1016/s1040-8428(02)00114-2.
   PubMed Web of Science ®Google Scholar
• Nicolae A, Ganapathi KA, Pham TH, et al. EBV-negative aggressive NK-cell leukemia/lymphoma: clinical, pathologic, and genetic features. Am J Surg Pathol. 2017;41(1):67–74. doi: 10.1097/PAS.0000000000000735.
   PubMed Web of Science ®Google Scholar
• Kimura H, Kwong YL. EBV viral loads in diagnosis, monitoring, and response assessment. Front Oncol. 2019;9:62. doi: 10.3389/fonc.2019.00062.
   PubMed Web of Science ®Google Scholar
• Kawada JI, Kamiya Y, Sawada A, et al. Viral DNA loads in various blood components of patients with Epstein-Barr virus-positive T-cell/natural killer cell lymphoproliferative diseases. J Infect Dis. 2019;220(8):1307–1311. doi: 10.1093/infdis/jiz315.
   PubMed Web of Science ®Google Scholar
• Kanakry JA, Hegde AM, Durand CM, et al. The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseases. Blood. 2016;127(16):2007–2017. doi: 10.1182/blood-2015-09-672030.
   PubMed Web of Science ®Google Scholar
• Au WY, Pang A, Choy C, et al. Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood. 2004;104(1):243–249. doi: 10.1182/blood-2003-12-4197.
   PubMed Web of Science ®Google Scholar
• Tse E, Kwong YL. Diagnosis and management of extranodal NK/T cell lymphoma nasal type. Expert Rev Hematol. 2016;9(9):861–871. doi: 10.1080/17474086.2016.1206465.
   PubMed Web of Science ®Google Scholar
• Suzuki R, Yamaguchi M, Izutsu K, et al. Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type. Blood. 2011;118(23):6018–6022. doi: 10.1182/blood-2011-05-354142.
   PubMed Web of Science ®Google Scholar
• Fournier B, Boutboul D, Bruneau J, et al. Rapid identification and characterization of infected cells in blood during chronic active Epstein-Barr virus infection. J Exp Med. 2020;217(11):e20192262. doi: 10.1084/jem.20192262.
   PubMed Web of Science ®Google Scholar
• Abe N, Fujieda Y. Chronic active Epstein-Barr virus infection. Blood. 2020;136(18):2090–2090. doi: 10.1182/blood.2020008157.
   PubMed Web of Science ®Google Scholar
• Syrykh C, Péricart S, Lamaison C, et al. Epstein-Barr virus-associated T- and NK-cell lymphoproliferative diseases: a review of clinical and pathological features. Cancers (Basel). 2021;13(13):3315. doi: 10.3390/cancers13133315.
   PubMed Web of Science ®Google Scholar
• Tripodi SA, Rocca BJ, Hako L, et al. Quality control by tissue microarray in immunohistochemistry. J Clin Pathol. 2012;65(7):635–637. doi: 10.1136/jclinpath-2011-200551.
   PubMed Web of Science ®Google Scholar
• Dojcinov SD, Fend F, Quintanilla-Martinez L. EBV-Positive lymphoproliferations of B- T- and NK-cell derivation in Non-Immunocompromised hosts. Pathogens. 2018;7(1):28. doi: 10.3390/pathogens7010028.
   PubMed Web of Science ®Google Scholar
• Takahashi E, Ohshima K, Kimura H, et al. Clinicopathological analysis of the age-related differences in patients with Epstein-Barr virus (EBV)-associated extranasal natural killer (NK)/T-cell lymphoma with reference to the relationship with aggressive NK cell leukaemia and chronic active EBV infection-associated lymphoproliferative disorders. Histopathology. 2011;59(4):660–671. doi: 10.1111/j.1365-2559.2011.03976.x.
   PubMed Web of Science ®Google Scholar
• Hu X, Yang Y, Chen L, et al. Chronic active Epstein-Barr virus infection progresses to aggressive NK cell leukemia with a poor prognosis. Am J Transl Res. 2021;13(10):12006–12015.
   PubMed Web of Science ®Google Scholar
• Fox CP, Haigh TA, Taylor GS, et al. A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy. Blood. 2010;116(19):3695–3704. doi: 10.1182/blood-2010-06-292268.
   PubMed Web of Science ®Google Scholar
• Nakashima Y, Tagawa H, Suzuki R, et al. Genome-wide array-based comparative genomic hybridization of natural killer cell lymphoma/leukemia: different genomic alteration patterns of aggressive NK-cell leukemia and extranodal Nk/T-cell lymphoma, nasal type. Genes Chromosomes Cancer. 2005;44(3):247–255. doi: 10.1002/gcc.20245.
   PubMed Web of Science ®Google Scholar
• Montes-Mojarro IA, Fend F, Quintanilla-Martinez L. EBV and the pathogenesis of NK/T cell lymphoma. Cancers (Basel). 2021;13(6):1414. doi: 10.3390/cancers13061414.
   PubMed Web of Science ®Google Scholar
• Palendira U, Rickinson AB. Primary immunodeficiencies and the control of Epstein-Barr virus infection. Ann N Y Acad Sci. 2015;1356(1):22–44. doi: 10.1111/nyas.12937.
   PubMedGoogle Scholar
• Li Z, Tsai MH, Shumilov A, et al. Epstein-Barr virus ncRNA from a nasopharyngeal carcinoma induces an inflammatory response that promotes virus production. Nat Microbiol. 2019;4(12):2475–2486. doi: 10.1038/s41564-019-0546-y.
   PubMed Web of Science ®Google Scholar
• Cohen JI. Primary immunodeficiencies associated with EBV disease. Curr Top Microbiol Immunol. 2015;390(Pt 1):241–265. doi: 10.1007/978-3-319-22822-8_10.
   PubMed Web of Science ®Google Scholar
• Tangye SG, Palendira U, Edwards ES. Human immunity against EBV-lessons from the clinic. J Exp Med. 2017;214(2):269–283. doi: 10.1084/jem.20161846.
   PubMed Web of Science ®Google Scholar
• Cai Q, Chen K, Young KH. Epstein-Barr virus-positive T/NK-cell lymphoproliferative disorders. Exp Mol Med. 2015;47(1):e133–e133. doi: 10.1038/emm.2014.105.
   PubMedGoogle Scholar
• Guan YQ, Shen KF, Yang L, et al. Inherited genetic susceptibility to nonimmunosuppressed Epstein-Barr virus-associated T/NK-cell lymphoproliferative diseases in chinese patients. Curr Med Sci. 2021;41(3):482–490. doi: 10.1007/s11596-021-2375-5.
   PubMed Web of Science ®Google Scholar
• Rodriguez R, Fournier B, Cordeiro DJ, et al. Concomitant PIK3CD and TNFRSF9 deficiencies cause chronic active Epstein-Barr virus infection of T cells. J Exp Med. 2019;216(12):2800–2818. doi: 10.1084/jem.20190678.
   PubMed Web of Science ®Google Scholar
• Okuno Y, Murata T, Sato Y, et al. Genetic background of chronic active Epstein-Barr virus disease. Blood. 2017;130(Supplement 1):1468–1468.
   PubMedGoogle Scholar
• Ishimura M, Eguchi K, Shiraishi A, et al. Systemic Epstein-Barr virus-positive T/NK lymphoproliferative diseases with SH2D1A/XIAP hypomorphic gene variants. Front Pediatr. 2019;7:183. doi: 10.3389/fped.2019.00183.
   PubMed Web of Science ®Google Scholar
• Gao LM, Zhao S, Zhang WY, et al. Somatic mutations in KMT2D and TET2 associated with worse prognosis in Epstein-Barr virus-associated T or natural killer-cell lymphoproliferative disorders. Cancer Biol Ther. 2019;20(10):1319–1327. doi: 10.1080/15384047.2019.1638670.
   PubMed Web of Science ®Google Scholar
• Li Z, Xia Y, Feng LN, et al. Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study. Lancet Oncol. 2016;17(9):1240–1247. doi: 10.1016/S1470-2045(16)30148-6.
   PubMed Web of Science ®Google Scholar
• Jiang L, Gu ZH, Yan ZX, et al. Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma. Nat Genet. 2015;47(9):1061–1066. doi: 10.1038/ng.3358.
   PubMed Web of Science ®Google Scholar
• Huang L, Liu D, Wang N, et al. Integrated genomic analysis identifies deregulated JAK/STAT-MYC-biosynthesis axis in aggressive NK-cell leukemia. Cell Res. 2018;28(2):172–186. doi: 10.1038/cr.2017.146.
   PubMed Web of Science ®Google Scholar
• Yuan L, Kan Y, Meeks JK, et al. 18F-FDG PET/CT for identifying the potential causes and extent of secondary hemophagocytic lymphohistiocytosis. Diagn Interv Radiol. 2016;22(5):471–475. doi: 10.5152/dir.2016.15226.
   PubMed Web of Science ®Google Scholar
• Tse E, Kwong YL. The diagnosis and management of NK/T-cell lymphomas. J Hematol Oncol. 2017;10(1):85. doi: 10.1186/s13045-017-0452-9.
   PubMed Web of Science ®Google Scholar
• Lu X, Kan Y, Wang W, et al. Primary cutaneous natural killer/T-cell lymphoma: a posttransplant lymphoproliferative disorder demonstrated by 18F-FDG PET/CT. Clin Nucl Med. 2021;46(7):595–598. doi: 10.1097/RLU.0000000000003524.
   PubMed Web of Science ®Google Scholar
• Hao R, Yang X, Liu Z, et al. EBV-Associated T-cell lymphoproliferative disorders demonstrated on FDG PET/CT in a patient with hemophagocytic lymphohistiocytosis. Clin Nucl Med. 2019;44(10):829–830. doi: 10.1097/RLU.0000000000002649.
   PubMed Web of Science ®Google Scholar
• Toriihara A, Nakajima R, Arai A, et al. Pathogenesis and FDG-PET/CT findings of Epstein-Barr virus-related lymphoid neoplasms. Ann Nucl Med. 2017;31(6):425–436. doi: 10.1007/s12149-017-1180-5.
   PubMed Web of Science ®Google Scholar
• Wass M, Bauer M, Pfannes R, et al. Chronic active Epstein-Barr virus infection of T-cell type, systemic form in an african migrant: case report and review of the literature on diagnostics standards and therapeutic options. BMC Cancer. 2018;18(1):941. doi: 10.1186/s12885-018-4861-0.
   PubMedGoogle Scholar
• Yang X, Lu X, Kan Y, et al. Muscle involvement caused by chronic active Epstein-Barr virus infection on 18F-FDG PET/CT in a pediatric patient. Clin Nucl Med. 2022;47(3):268–270. doi: 10.1097/RLU.0000000000003899.
   PubMed Web of Science ®Google Scholar
• Tseng YJ, Ding WQ, Zhong L, et al. Chronic active Epstein-Barr virus (CAEBV) enteritis. Int J Infect Dis. 2019;82:15–17. doi: 10.1016/j.ijid.2019.02.020.
   PubMed Web of Science ®Google Scholar
• Pu Q, Cao X, Liu Y, et al. Comprehensive analysis and summary of the value of immunophenotypes of mature NK cell tumors for differential diagnosis, treatment, and prognosis. Front Immunol. 2022;13:918487. doi: 10.3389/fimmu.2022.918487.
   PubMed Web of Science ®Google Scholar
• Yachie A. Cytologic analysis of Epstein-Barr virus-associated T/natural Killer-Cell lymphoproliferative diseases. Front Pediatr. 2018;6:327. doi: 10.3389/fped.2018.00327.
   PubMed Web of Science ®Google Scholar
• Jevremovic D, Olteanu H. Flow cytometry applications in the diagnosis of T/NK-cell lymphoproliferative disorders. Cytometry B Clin Cytom. 2019;96(2):99–115. doi: 10.1002/cyto.b.21768.
   PubMed Web of Science ®Google Scholar
• Carvelli J, Piperoglou C, Farnarier C, et al. Functional and genetic testing in adults with HLH reveals an inflammatory profile rather than a cytotoxicity defect. Blood. 2020;136(5):542–552. doi: 10.1182/blood.2019003664.
   PubMed Web of Science ®Google Scholar
• Perussia B, Starr S, Abraham S, et al. Human natural killer cells analyzed by B73.1, a monoclonal antibody blocking Fc receptor functions. I. Characterization of the lymphocyte subset reactive with B73.1. J Immunol. 1983;130(5):2133–2141. doi: 10.4049/jimmunol.130.5.2133.
   PubMed Web of Science ®Google Scholar
• Lanier LL, Chang C, Azuma M, et al. Molecular and functional analysis of human natural killer cell-associated neural cell adhesion molecule (N-CAM/CD56). J Immunol (Baltimore, Md, 1950). 1991;146(12):4421–4426. doi: 10.4049/jimmunol.146.12.4421.
   PubMed Web of Science ®Google Scholar
• Morice WG. The immunophenotypic attributes of NK cells and NK-cell lineage lymphoproliferative disorders. Am J Clin Pathol. 2007;127(6):881–886. doi: 10.1309/Q49CRJ030L22MHLF.
   PubMed Web of Science ®Google Scholar
• Morice WG, Kurtin PJ, Leibson PJ, et al. Demonstration of aberrant T-cell and natural killer-cell antigen expression in all cases of granular lymphocytic leukaemia. Br J Haematol. 2003;120(6):1026–1036. doi: 10.1046/j.1365-2141.2003.04201.x.
   PubMed Web of Science ®Google Scholar
• Heibein JA, Goping IS, Barry M, et al. Granzyme B-mediated cytochrome c release is regulated by the bcl-2 family members bid and bax. J Exp Med. 2000;192(10):1391–1402. doi: 10.1084/jem.192.10.1391.
   PubMed Web of Science ®Google Scholar
• Doroshow DB, Bhalla S, Beasley MB, et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021;18(6):345–362. doi: 10.1038/s41571-021-00473-5.
   PubMed Web of Science ®Google Scholar
• Dębska-Zielkowska J, Moszkowska G, Zieliński M, et al. KIR receptors as key regulators of NK cells activity in health and disease. Cells. 2021;10(7):1777. doi: 10.3390/cells10071777.
   PubMed Web of Science ®Google Scholar
• Montaldo E, Del Zotto G, Della Chiesa M, et al. Human NK cell receptors/markers: a tool to analyze NK cell development, subsets and function. Cytometry A. 2013;83(8):702–713. doi: 10.1002/cyto.a.22302.
   PubMedGoogle Scholar
• Caligiuri MA, Zmuidzinas A, Manley TJ, et al. Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors. J Exp Med. 1990;171(5):1509–1526. doi: 10.1084/jem.171.5.1509.
   PubMed Web of Science ®Google Scholar
• Cooper MA, Fehniger TA, Turner SC, et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood. 2001;97(10):3146–3151. doi: 10.1182/blood.v97.10.3146.
   PubMed Web of Science ®Google Scholar
• Carson WE, Fehniger TA, Caligiuri MA. CD56bright natural killer cell subsets: characterization of distinct functional responses to interleukin-2 and the c-kit ligand. Eur J Immunol. 1997;27(2):354–360. doi: 10.1002/eji.1830270203.
   PubMed Web of Science ®Google Scholar
• Chan A, Hong DL, Atzberger A, et al. CD56bright human NK cells differentiate into CD56dim cells: role of contact with peripheral fibroblasts. J Immunol. 2007;179(1):89–94. doi: 10.4049/jimmunol.179.1.89.
   PubMed Web of Science ®Google Scholar
• Björkström NK, Riese P, Heuts F, et al. Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education. Blood. 2010;116(19):3853–3864. doi: 10.1182/blood-2010-04-281675.
   PubMed Web of Science ®Google Scholar
• Trotta R, Parihar R, Yu J, et al. Differential expression of SHIP1 in CD56bright and CD56dim NK cells provides a molecular basis for distinct functional responses to monokine costimulation. Blood. 2005;105(8):3011–3018. doi: 10.1182/blood-2004-10-4072.
   PubMed Web of Science ®Google Scholar
• Luetke-Eversloh M, Killig M, Romagnani C. Signatures of human NK cell development and terminal differentiation. Front Immunol. 2013;4:499. doi: 10.3389/fimmu.2013.00499.
   PubMed Web of Science ®Google Scholar
• Lünemann A, Vanoaica LD, Azzi T, et al. A distinct subpopulation of human NK cells restricts B cell transformation by EBV. J Immunol. 2013;191(10):4989–4995. doi: 10.4049/jimmunol.1301046.
   PubMed Web of Science ®Google Scholar
• Forconi CS, Oduor CI, Oluoch PO, et al. A new hope for CD56(neg)CD16(pos) NK cells as unconventional cytotoxic mediators: an adaptation to chronic diseases. Front Cell Infect Microbiol. 2020;10:162. doi: 10.3389/fcimb.2020.00162.
   PubMed Web of Science ®Google Scholar
• Jiang NG, Jin YM, Niu Q, et al. Flow cytometric immunophenotyping is of great value to diagnosis of natural killer cell neoplasms involving bone marrow and peripheral blood. Ann Hematol. 2013;92(1):89–96. doi: 10.1007/s00277-012-1574-3.
   PubMed Web of Science ®Google Scholar
• Müller-Durovic B, Grählert J, Devine OP, et al. CD56-negative NK cells with impaired effector function expand in CMV and EBV co-infected healthy donors with age. Aging (Albany NY). 2019;11(2):724–740. doi: 10.18632/aging.101774.
   PubMedGoogle Scholar
• Lu G, Xie ZD, Zhao SY, et al. Clinical analysis and follow-up study of chronic active Epstein-Barr virus infection in 53 pediatric cases. Chin Med J. 2009;122(3):262–266. doi: 10.3760/cma.j.issn.0366-6999.2009.03.005.
   PubMed Web of Science ®Google Scholar
• Luo L, Wang H, Fan H, et al. The clinical characteristics and the features of immunophenotype of peripheral lymphocytes of adult onset chronic active Epstein-Barr virus disease at a tertiary care hospital in beijing. Medicine (Baltimore). 2018;97(9):e9854. doi: 10.1097/MD.0000000000009854.
   PubMed Web of Science ®Google Scholar
• Wada T, Kurokawa T, Toma T, et al. Immunophenotypic analysis of Epstein-Barr virus (EBV)-infected CD8(+) T cells in a patient with EBV-associated hemophagocytic lymphohistiocytosis. Eur J Haematol. 2007;79(1):72–75. doi: 10.1111/j.1600-0609.2007.00868.x.
   PubMed Web of Science ®Google Scholar
• Miyawaki T, Kasahara Y, Kanegane H, et al. Expression of CD45R0 (UCHL1) by CD4+ and CD8+ T cells as a sign of in vivo activation in infectious mononucleosis. Clin Exp Immunol. 1991;83(3):447–451. doi: 10.1111/j.1365-2249.1991.tb05659.x.
   PubMed Web of Science ®Google Scholar
• Hirai Y, Yamamoto T, Kimura H, et al. Hydroa vacciniforme is associated with increased numbers of Epstein-Barr virus-infected γδT cells. J Invest Dermatol. 2012;132(5):1401–1408. doi: 10.1038/jid.2011.461.
   PubMed Web of Science ®Google Scholar
• Lima M. Extranodal NK/T cell lymphoma and aggressive NK cell leukaemia: evidence for their origin on CD56 + bright CD16-/+dim NK cells. Pathology. 2015;47(6):503–514. doi: 10.1097/PAT.0000000000000275.
   PubMed Web of Science ®Google Scholar
• Ng SB, Lai KW, Murugaya S, et al. Nasal-type extranodal natural killer/T-cell lymphomas: a clinicopathologic and genotypic study of 42 cases in Singapore. Mod Pathol. 2004;17(9):1097–1107. doi: 10.1038/modpathol.3800157.
   PubMed Web of Science ®Google Scholar
• de Mel S, Li JB, Abid MB, et al. The utility of flow cytometry in differentiating NK/T cell lymphoma from indolent and reactive NK cell proliferations. Cytometry B Clin Cytom. 2018;94(1):159–168. doi: 10.1002/cyto.b.21529.
   PubMed Web of Science ®Google Scholar
• Li C, Tian Y, Wang J, et al. Abnormal immunophenotype provides a key diagnostic marker: a report of 29 cases of de novo aggressive natural killer cell leukemia. Transl Res. 2014;163(6):565–577. doi: 10.1016/j.trsl.2014.01.010.
   PubMed Web of Science ®Google Scholar
• Ishida F. Aggressive NK-cell leukemia. Front Pediatr. 2018;6:292. doi: 10.3389/fped.2018.00292.
   PubMed Web of Science ®Google Scholar
• Rashidi A, Fisher SI. EBV-associated aggressive natural killer cell leukemia. Blood. 2016;127(20):2502–2502. doi: 10.1182/blood-2016-02-700682.
   PubMed Web of Science ®Google Scholar
• Falcão RP, Rizzatti EG, Saggioro FP, et al. Flow cytometry characterization of leukemic phase of nasal NK/T-cell lymphoma in tumor biopsies and peripheral blood. Haematologica. 2007;92(2):e24-25–e25. doi: 10.3324/haematol.10654.
   Web of Science ®Google Scholar
• Lima M, Spínola A, Fonseca S, et al. Aggressive mature natural killer cell neoplasms: report on a series of 12 european patients with emphasis on flow cytometry based immunophenotype and DNA content of neoplastic natural killer cells. Leuk Lymphoma. 2015;56(1):103–112. doi: 10.3109/10428194.2014.905772.
   PubMed Web of Science ®Google Scholar
• Raspadori D, Damiani D, Lenoci M, et al. CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis. Leukemia. 2001;15(8):1161–1164. doi: 10.1038/sj.leu.2402174.
   PubMed Web of Science ®Google Scholar
• Aloysius MM, Zaitoun AM, Awad S, et al. Mucins and CD56 as markers of tumour invasion and prognosis in periampullary cancer. Br J Surg. 2010;97(8):1269–1278. doi: 10.1002/bjs.7107.
   PubMed Web of Science ®Google Scholar
• Au WY, Ma SY, Chim CS, et al. Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the world health organization classification scheme: a single center experience of 10 years. Ann Oncol. 2005;16(2):206–214. doi: 10.1093/annonc/mdi037.
   PubMed Web of Science ®Google Scholar
• Feng Y, Feng X, Jing C, et al. The expression and clinical significance of programmed cell death receptor 1 and its ligand in tumor tissues of patients with extranodal nasal NK/T cell lymphoma. Sci Rep. 2022;12(1):36. doi: 10.1038/s41598-021-02515-5.
   PubMed Web of Science ®Google Scholar